Key Details
Price
$6.92Annual ROE
-63.15%Beta
1.16Events Calendar
Next earnings date:
Jan 03, 2025Recent quarterly earnings:
Oct 03, 2024Recent annual earnings:
July 16, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million.
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
FAQ
- What is the primary business of AngioDynamics?
- What is the ticker symbol for AngioDynamics?
- Does AngioDynamics pay dividends?
- What sector is AngioDynamics in?
- What industry is AngioDynamics in?
- What country is AngioDynamics based in?
- When did AngioDynamics go public?
- Is AngioDynamics in the S&P 500?
- Is AngioDynamics in the NASDAQ 100?
- Is AngioDynamics in the Dow Jones?
- When was AngioDynamics's last earnings report?
- When does AngioDynamics report earnings?
- Should I buy AngioDynamics stock now?